MedTrace Logo

Raltegravir Treatment in Patients Failing Highly Active Antiretroviral Therapy (HAART) in Denmark

NCT01061957 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2010-02-04

No results posted yet for this study

Summary

Raltegravir is the first integrase inhibitor approved for treatment of HIV infected patients harboring multiresistant viruses. The drug has been proved effective in both trials and clinical settings, but the long-term efficacy is not described and the effect compared to treatment in Highly active antiretroviral therapy (HAART) naive patients remains to be established.

Conditions

  • HIV Infections

Sponsors & Collaborators

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-07-31
Completion
2009-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01061957 on ClinicalTrials.gov